Lux Capital, an investment firm, Union Square Ventures, a venture capital firm, and Maveron, a consumer-only venture capital firm, led a $22m Series A round in Alife, a fertility technology company building artificial intelligence tools to advance in-vitro fertilization. “USV has long focused on partnering with businesses that have strong network effects with the belief that networks create significant value for both company and customer. Alife is powerfully demonstrating this in fertility by applying advanced AI to large datasets to offer intelligent fertility care to patients and in a software wrapper that makes adoption by practitioners simple and effective. Nothing will change the fertility landscape in a more significant way than improving efficacy per cycle and lowering cost. Alife is at the forefront of creating this value and we’re thrilled to work with Paxton and his fantastic team as their products become standard practice in fertility treatments worldwide,” Rebecca Kaden, Union Square Ventures Managing Partner.